What is it about?
TIMP-2 is an endogeneous metalloprotease inhibitor that have shown anti-proliferative, anti- angiogenic and anti-metastatic activity. Recombinant human TIMP-2 is a promising and attractive biotherapeutic candidate. Using self-assembling, biodegradable peptide hydrogels previously developed we were able to show effective encapsulation of rhTIMP-2 while the hydrogels still maintain malleability. Encapsulated rhTIMP-2 was slowly released to upto 28 days and maintained all anti-cancer properties to that of unformulated rhTIMP-2 .
Featured Image
Why is it important?
This work allows for the development of an injectable formulation of an attractive anti-cancer bio-therapeutic candidate-rhTIMP-2. We were therefore able to develop an injectable dosage form that serves as a biological depot at the site of injection and leads to an extended release of the biologically active protein to up-to a month. This will enable further pre-clinical/clical studies without the need of daily administration and an attractive formulation method in general for related pharmacologically active biologic candidates.
Perspectives
This work is a result of long standing collaboration between two laboratories with diverse expertise. Researchers and Clinicians should consider similar biodegradable encapsulation strategies that can allow sustained release of the biotherapeutics they are working with.
Dr. Ananda Chowdhury
National Cancer Institute, National Institutes of Health
Read the Original
This page is a summary of: Macromolecule-Network Electrostatics Controlling Delivery of the Biotherapeutic Cell Modulator TIMP-2, Biomacromolecules, March 2018, American Chemical Society (ACS),
DOI: 10.1021/acs.biomac.8b00107.
You can read the full text:
Contributors
The following have contributed to this page
